A group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities is acute myeloid leukemia (AML). Mutations of CEBPA, a tumour suppressor, are found in about 10 per cent of human AML patients. In two separate studies on CEBPA mutations in AML subtypes, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates ...
Read More
No comments:
Post a Comment